March 12, 2020 / 11:18 AM / 2 months ago

BRIEF-Roche Gets EU Approval For Chronic Lymphocytic Leukaemia Treatment

March 12 (Reuters) - Roche Holding AG:

* EUROPEAN COMMISSION APPROVES VENCLYXTO PLUS GAZYVARO FOR ADULTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA

* COMBINATION REGIMEN OFFERS A NEW 12-MONTH, FIXED-DURATION, CHEMOTHERAPY-FREE TREATMENT OPTION FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

* RESULTS OF THE PHASE III CLL14 STUDY ADD TO THE GROWING BODY OF EVIDENCE SUPPORTING THE POTENTIAL OF VENCLYXTO-BASED COMBINATIONS ACROSS MULTIPLE LINES

* DATA SHOWED THAT A FIXED DURATION OF TREATMENT WITH VENCLYXTO PLUS GAZYVARO REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 65% COMPARED TO A CURRENT STANDARD-OF-CARE Source text: bit.ly/2wUPnIP Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below